A mechanism-based prognostic enrichment strategy for the development of the TREM-1 inhibitor nangibotide in septic shock.

COI Statement

Declarations. Conflicts of interest: BF, ML, PFL and RF were members of the ASTONISH study steering committee. BF reports personal fees for consulting from Inotrem, Eagle and Enlivex outside of the submitted work and support for attending a meeting from Inotrem. PFL reports consulting fees from Adrenomed and Inotrem outside of the submitted work. RF reports personal fees from Inotrem, during the conduct of the study and personal fees from Shionogi, Pfizer, MSD, Thermofisher, Menarini, Cytosorbent, Gilead, Viatris, AOP and Grifols outside of the submitted work. DA reports consulting agreement with Inotrem outside of the submitted work. ML reports receiving a grant (1R01HL162954-01) outside of the submitted work. RF is Deputy Editor of the Intensive Care Medicine journal. Ethical approval: The trial procedures and the informed consent form process were approved by the respective independent ethics committees following international standards, the national requirements of each participating country and the 1964 Declaration of Helsinki and its later amendments. The study was registered in the EU Clinical Trials Register (EudraCT number 2018-004827-36) and with Clinicaltrials.gov, NCT04055909. Consent to participate: Informed consent was obtained from all individual participants included in the study.

References:

• Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315(8):801–810
• Vincent J-L, van der Poll T, Marshall JC (2022) The end of “one size fits all” sepsis therapies: toward an individualized approach. Biomedicines 10(9):2260
• Llitjos J-F, Carrol ED, Osuchowski MF, Bonneville M, Scicluna BP, Payen D, Randolph AG, Witte S, Rodriguez-Manzano J, François B (2024) Enhancing sepsis biomarker development: key considerations from public and private perspectives. Crit Care 28(1):238
• Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, Berry S, Clermont G, Cooper G, Gomez H, Huang DT, Kellum JA, Mi Q, Opal SM, Talisa V, van der Poll T, Visweswaran S, Vodovotz Y, Weiss JC, Yealy DM, Yende S, Angus DC (2019) Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 321(20):2003–2017
• François B, Lambden S, Fivez T, Gibot S, Derive M, Grouin J-M, Salcedo-Magguilli M, Lemarié J, de Schryver N, Jalkanen V, Hicheur T, Garaud J-J, Cuvier V, Ferrer R, Bestle M, Pettilä V, Mira J-P, Bouisse C, Mercier E, Vermassen J, Huberlant V, Vinatier I, Anguel N, Levy M, Laterre P-F (2023) Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial. Lancet Respir Med 11(10):894–904